LATAGLIATA, Angelo Raffaele
LATAGLIATA, Angelo Raffaele
Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront
2015 Breccia, M; Molica, Matteo; Colafigli, Gioia; Zacheo, I; Latagliata, Angelo Raffaele; Tafuri, Agostino; Alimena, Giuliana
Decisional flow with a score system to start platelet-lowering treatment in patients with essential thrombocythemia (ET): Long-term results
2007 Latagliata, Angelo Raffaele; Rago, A; Spadea, A; Santoro, Cristina; Carmosino, I; Breccia, M; Napoleone, L; Fama, A; Biondo, F; Volpicelli, P; Petti, Mc; Alimena, Giuliana; Mazzucconi, Maria Gabriella
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response
2016 Latagliata, R.; Romano, A.; Mancini, M.; Breccia, Massimo; Carmosino, I.; Vozella, F.; Montagna, C.; Volpicelli, P.; De Angelis, F.; Petrucci, L.; Serrao, A.; Molica, M.; Salaroli, A.; Diverio, D.; Alimena, G.
Elderly patients with PH+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment
2005 Latagliata, R.; Breccia, M.; Carmosino, I.; Sarlo, C.; Montefusco, E.; Mancini, M.; Natalino, F.; Chistolini, A.; De Cuia, R.; Russo, E.; Morano, G. S.; Biondo, F.; Spadea, A.; Mandelli, F.; Alimena, G.
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia
2020 Cesini, L.; Frieri, C.; Barate, C.; Sora, F.; Bonifacio, M.; Cerrano, M.; Cagnetta, A.; Elena, C.; Aprile, L.; Sgherza, N.; Trawinska, M.; Gozzini, A.; Capodanno, I.; Crugnola, M.; Carmosino, I.; Scalzulli, E.; Ricci, F.; Bocchia, M.; Bergamaschi, M.; Aguzzi, C.; Sica, S.; Galimberti, S.; Breccia, M.; Luciano, L.; Latagliata, R.
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib
2019 Cesini, L.; Carmosino, I.; Breccia, M.; De Benedittis, D.; Mohamed, S.; De Luca, M. L.; Colafigli, G.; Molica, M.; Scalzulli, E.; Massaro, F.; Mariggio, E.; Rizzo, L.; Loglisci, M. G.; Scamuffa, M. C.; Vozella, F.; Diverio, D.; Mancini, M.; Alimena, G.; Foa, R.; Latagliata, R.
Mitoxantrone, Etoposide and Intermediate-dose Ara-c (mec) - An Effective Regimen For Poor Risk Acute Myeloid-leukemia
1993 Spadea, A; Petti, Mc; Fazi, P; Vegna, Ml; Arcese, W; Avvisati, G; ALOE SPIRITI, Maria Antonietta; Latagliata, R; Meloni, G; Testi, Am; Et, Al.
PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count
2020 Scamuffa, M. C.; Morano, S. G.; Serrao, A.; Bruzzese, A.; Stocchi, F.; Santoro, C.; Vozella, F.; Latagliata, R.; Chistolini, A.
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience
2020 Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M.
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment
2020 Latagliata, R.; Niscola, P.; Fianchi, L.; Aloe Spiriti, M. A.; Maurillo, L.; Carmosino, I.; Cesini, L.; Sarlo, C.; Piccioni, A.; Campagna, A.; De Luca, M. L.; De Benedittis, D.; Mancini, M.; Breccia, M.; Criscuolo, M.; Buccisano, F.; Voso, M. T.; Avvisati, G.; Tafuri, A.; De Fabritiis, P.; Foa, R.; Girmenia, C.
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
2021 Scalzulli, E.; Caocci, G.; Efficace, F.; Rizzo, L.; Colafigli, G.; Di Prima, A.; Pepe, S.; Fegatelli, D. A.; Carmosino, I.; Diverio, D.; Latagliata, R.; La Nasa, G.; Martelli, M.; Foa, R.; Breccia, M.
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up
2021 Scalzulli, E.; Colafigli, G.; Pepe, S.; De Luca, G.; Di Prima, A.; Efficace, F.; Diverio, D.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M.
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients
2020 Scalzulli, E.; Colafigli, G.; Latagliata, R.; Pepe, S.; Diverio, D.; Stocchi, F.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M.
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life
2019 Molica, M.; Colafigli, G.; Scalzulli, E.; Alunni Fegatelli, D.; CHIATAMONE RANIERI, Sofia; Rizzo, L.; Diverio, D.; Efficace, F.; Latagliata, R.; Foa, R.; Breccia, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront | 2015 | Breccia, M; Molica, Matteo; Colafigli, Gioia; Zacheo, I; Latagliata, Angelo Raffaele; Tafuri, Agostino; Alimena, Giuliana | |
| Decisional flow with a score system to start platelet-lowering treatment in patients with essential thrombocythemia (ET): Long-term results | 2007 | Latagliata, Angelo Raffaele; Rago, A; Spadea, A; Santoro, Cristina; Carmosino, I; Breccia, M; Napoleone, L; Fama, A; Biondo, F; Volpicelli, P; Petti, Mc; Alimena, Giuliana; Mazzucconi, Maria Gabriella | |
| Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response | 2016 | Latagliata, R.; Romano, A.; Mancini, M.; Breccia, Massimo; Carmosino, I.; Vozella, F.; Montagna, C.; Volpicelli, P.; De Angelis, F.; Petrucci, L.; Serrao, A.; Molica, M.; Salaroli, A.; Diverio, D.; Alimena, G. | |
| Elderly patients with PH+ chronic myelogenous leukemia (CML): Results of imatinib mesylate treatment | 2005 | Latagliata, R.; Breccia, M.; Carmosino, I.; Sarlo, C.; Montefusco, E.; Mancini, M.; Natalino, F.; Chistolini, A.; De Cuia, R.; Russo, E.; Morano, G. S.; Biondo, F.; Spadea, A.; Mandelli, F.; Alimena, G. | |
| Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia | 2020 | Cesini, L.; Frieri, C.; Barate, C.; Sora, F.; Bonifacio, M.; Cerrano, M.; Cagnetta, A.; Elena, C.; Aprile, L.; Sgherza, N.; Trawinska, M.; Gozzini, A.; Capodanno, I.; Crugnola, M.; Carmosino, I.; Scalzulli, E.; Ricci, F.; Bocchia, M.; Bergamaschi, M.; Aguzzi, C.; Sica, S.; Galimberti, S.; Breccia, M.; Luciano, L.; Latagliata, R. | |
| Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib | 2019 | Cesini, L.; Carmosino, I.; Breccia, M.; De Benedittis, D.; Mohamed, S.; De Luca, M. L.; Colafigli, G.; Molica, M.; Scalzulli, E.; Massaro, F.; Mariggio, E.; Rizzo, L.; Loglisci, M. G.; Scamuffa, M. C.; Vozella, F.; Diverio, D.; Mancini, M.; Alimena, G.; Foa, R.; Latagliata, R. | |
| Mitoxantrone, Etoposide and Intermediate-dose Ara-c (mec) - An Effective Regimen For Poor Risk Acute Myeloid-leukemia | 1993 | Spadea, A; Petti, Mc; Fazi, P; Vegna, Ml; Arcese, W; Avvisati, G; ALOE SPIRITI, Maria Antonietta; Latagliata, R; Meloni, G; Testi, Am; Et, Al. | |
| PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count | 2020 | Scamuffa, M. C.; Morano, S. G.; Serrao, A.; Bruzzese, A.; Stocchi, F.; Santoro, C.; Vozella, F.; Latagliata, R.; Chistolini, A. | |
| Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience | 2020 | Pepe, S.; Scalzulli, E.; Colafigli, G.; Di Prima, A.; Diverio, D.; Mancini, M.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M. | |
| Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment | 2020 | Latagliata, R.; Niscola, P.; Fianchi, L.; Aloe Spiriti, M. A.; Maurillo, L.; Carmosino, I.; Cesini, L.; Sarlo, C.; Piccioni, A.; Campagna, A.; De Luca, M. L.; De Benedittis, D.; Mancini, M.; Breccia, M.; Criscuolo, M.; Buccisano, F.; Voso, M. T.; Avvisati, G.; Tafuri, A.; De Fabritiis, P.; Foa, R.; Girmenia, C. | |
| Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients | 2021 | Scalzulli, E.; Caocci, G.; Efficace, F.; Rizzo, L.; Colafigli, G.; Di Prima, A.; Pepe, S.; Fegatelli, D. A.; Carmosino, I.; Diverio, D.; Latagliata, R.; La Nasa, G.; Martelli, M.; Foa, R.; Breccia, M. | |
| Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up | 2021 | Scalzulli, E.; Colafigli, G.; Pepe, S.; De Luca, G.; Di Prima, A.; Efficace, F.; Diverio, D.; Latagliata, R.; Martelli, M.; Foa, R.; Breccia, M. | |
| Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients | 2020 | Scalzulli, E.; Colafigli, G.; Latagliata, R.; Pepe, S.; Diverio, D.; Stocchi, F.; Di Prima, A.; Efficace, F.; Martelli, M.; Foa, R.; Breccia, M. | |
| Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life | 2019 | Molica, M.; Colafigli, G.; Scalzulli, E.; Alunni Fegatelli, D.; CHIATAMONE RANIERI, Sofia; Rizzo, L.; Diverio, D.; Efficace, F.; Latagliata, R.; Foa, R.; Breccia, M. |